Nuvation Bio
NUVB
148 hedge funds and large institutions have $447M invested in Nuvation Bio in 2024 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 46 increasing their positions, 39 reducing their positions, and 17 closing their positions.
147% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 17
50% more call options, than puts
Call options by funds: $30K | Put options by funds: $20K
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
19% more funds holding
Funds holding: 124 → 148 (+24)
18% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 39
0.17% more ownership
Funds ownership: 61.75% → 61.92% (+0.17%)
9% less capital invested
Capital invested by funds: $490M → $447M (-$43.1M)
Top Buyers
| 1 |
DC
Decheng Capital
Menlo Park,
California
|
+$21.2M |
| 2 |
BlackRock
New York
|
+$11.3M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.96M |
| 4 |
LCM
Laurion Capital Management
New York
|
+$4.86M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$3.51M |
Top Sellers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.46M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
-$2.88M |
| 3 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$2.43M |
| 4 |
D.E. Shaw & Co
New York
|
-$2.1M |
| 5 |
SCM
Sio Capital Management
New York
|
-$2.04M |
NUVB Hedge Fund Activity: Q2 2024 in Review
148 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Nuvation Bio (NUVB) for Q2 2024, worth a combined $447M — down 8.8% from $490M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new NUVB positions and 17 closed out — a net gain of 25 holders — while 46 added to existing stakes and 39 trimmed.
The largest buyer was Decheng Capital, opening a new position worth an estimated $21.2M. The largest seller was T. Rowe Price Associates, cutting an estimated $3.46M.
- 148 institutional investors held Nuvation Bio (NUVB) as of Q2 2024, up from 124 in Q1 2024.
- Funds reported $447M of Nuvation Bio stock for Q2 2024, down 8.8% quarter-over-quarter.
- 42 funds opened new Nuvation Bio positions in Q2 2024 and 17 closed out, a net change of +25 holders.
- The largest Nuvation Bio buyer in Q2 2024 was Decheng Capital, an estimated $21.2M added.
- The largest Nuvation Bio seller in Q2 2024 was T. Rowe Price Associates, an estimated $3.46M sold.
Based on aggregated 13F filings for Q2 2024.